



# BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.  
PHONE:+044-25267517/25270992/42677555, FAX:91-44-25231264, mail: info@bafnapharma.com, website: www.bafnapharma.com  
CIN: L24294TN1995PLC030698

August 8, 2017

Listing Department  
The Bombay Stock Exchange Limited  
P J Towers  
Dalal Street  
Mumbai – 400 001

Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E)  
Mumbai – 400051

SCRIP CODE: 532989  
SCRIP SYMBOL: BAFNAPHARM  
ISIN: INE878I01014

Dear Sir,

Sub: Outcome of 165<sup>th</sup> (3/2017-18) Board Meeting  
Ref: Regulation 30 of SEBI (LODR) Regulations, 2015

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that, the Board of Directors of the Company in its meeting held on Tuesday, the 8<sup>th</sup> day of August, 2017 which commenced at 02.00 P.M and concluded at 6.50 P.M, inter alia transacted the following:

1. Considered and approved Unaudited Financial Statements for the quarter ended 30<sup>th</sup> June, 2017
2. Resignation of Ms. Sapna Jain, Company Secretary.

This is for your information and records.

Thanking you,

Yours faithfully,  
For BAFNA PHARMACEUTICALS LIMITED

Mahaveer Chand Bafna  
Managing Director  
(DIN: 01458211)